DRMA Stock Analysis: Buy, Sell, or Hold?
DRMA - Dermata Therapeutics, Inc. Common Stock
$1.42
0.04 (2.90%)
▲
5d:
-2.74%
30d:
+12.7%
90d:
+14.52%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 12, 2026
0d
Get Alerted When DRMA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: DRMA shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: DRMA shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: DRMA is currently trading at $1.42, which is considered extended relative to its 30-day fair value range of $1.14 to $1.41.
Technical Outlook: Technically, DRMA is showing sideways momentum. Immediate support is located at $1.06, while resistance sits at $1.62.
Market Sentiment: DRMA scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $4.00 (+181.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, DRMA is showing sideways momentum. Immediate support is located at $1.06, while resistance sits at $1.62.
Market Sentiment: DRMA scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $4.00 (+181.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$1.14 -
$1.41
Company Quality Score
37/100
(SELL)
Volume Confirmation
MODERATE
Confidence Score
21.1%
All Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (0/100)
- BULLISH: Trading 181.7% below Wall St target ($4.00)
- WARNING: Composite score 37/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.14 -
$1.41
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$1.06
Resistance Level
$1.62
Current Trend
Sideways
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.99
Wall Street Target
$4.00
(+181.7%)
Share & Embed Analysis
Last updated: August 22, 2026 9:39 PM ET
Data refreshes hourly during market hours. Next update: 10:39 PM
Data refreshes hourly during market hours. Next update: 10:39 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DRMA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 58 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$53 | 57 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$92 | 54 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 53 HOLD |
